MGX · Metagenomi Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| BAYER HEALTHCARE LLC 10% Owner | ▼ Sell | Other | 4,050,997 Shares held | 2/13/2024 | View profile |
| Thomas Brian C. Chief Executive Officer | ▼ Sell | Open Market | 2,510,960 Shares held | 12/5/2025 | View profile |
| Bernales Sebastian | ▼ Sell | Other | 1,896,445 Shares held | 2/13/2024 | View profile |
| Novo Holdings A/S 10% Owner | ▲ Buy | Open Market | 1,739,175 Shares held | 2/13/2024 | View profile |
| Irish Jian See Remarks | ▼ Sell | Open Market | 375,393 Shares held | 9/8/2026 | View profile |
| Wapnick Pamela Chief Financial Officer | ▼ Sell | Open Market | 206,580 Shares held | 9/8/2026 | View profile |
| Wein Matthew See Remarks | ▼ Sell | Open Market | 126,133 Shares held | 9/8/2026 | View profile |
| Harnest Simon See Remarks | ▲ Buy | Grant | 122,664 Shares held | 4/1/2024 | View profile |
| Noonberg Sarah B. Chief Medical Officer | ▼ Sell | Open Market | 109,135 Shares held | 6/6/2025 | View profile |
| Delaney Simren See Remarks | ▲ Buy | Grant | 93,892 Shares held | 4/1/2024 | View profile |
| Borges Luis Chief Scientific Officer | ▲ Buy | Grant | 69,316 Shares held | 4/1/2024 | View profile |
| Reid Laurence | ▲ Buy | Open Market | 20,000 Shares held | 9/9/2026 | View profile |
Transaction History
| Reid Laurence | ▲ Buy | Open Market | 19,883 | $23K | 9/9/2026 |
| Reid Laurence | ▲ Buy | Open Market | 117 | $138 | 9/9/2026 |
| Wein Matthew | ▼ Sell | Open Market | 358 | $415 | 9/8/2026 |
| Irish Jian | ▼ Sell | Open Market | 2,140 | $2K | 9/8/2026 |
| Wapnick Pamela | ▼ Sell | Open Market | 1,911 | $2K | 9/8/2026 |
| Wapnick Pamela | ▼ Sell | Open Market | 2,884 | $4K | 6/5/2026 |
| Irish Jian | ▼ Sell | Open Market | 3,737 | $5K | 6/5/2026 |
| Wein Matthew | ▼ Sell | Open Market | 558 | $725 | 6/5/2026 |
| Irish Jian | ▲ Buy | Grant | 46,000 | $0 | 4/1/2026 |
| Wein Matthew | ▲ Buy | Grant | 11,000 | $0 | 4/1/2026 |
| Wapnick Pamela | ▲ Buy | Grant | 24,000 | $0 | 4/1/2026 |
| Wapnick Pamela | ▼ Sell | Open Market | 1,581 | $3K | 3/5/2026 |
| Wein Matthew | ▼ Sell | Open Market | 482 | $771 | 3/5/2026 |
| Irish Jian | ▼ Sell | Open Market | 1,607 | $3K | 3/5/2026 |
| Irish Jian | ▼ Sell | Gift | 228,462 | $0 | 12/5/2025 |
| Thomas Brian C. | ▼ Sell | Open Market | 3,830 | $7K | 12/5/2025 |
| Wein Matthew | ▼ Sell | Open Market | 199 | $353 | 12/5/2025 |
| Wapnick Pamela | ▼ Sell | Open Market | 1,576 | $3K | 12/5/2025 |
| Irish Jian | ▼ Sell | Open Market | 1,602 | $3K | 12/5/2025 |
| Wapnick Pamela | ▲ Buy | Grant | 120,000 | $192K | 12/1/2025 |
| Irish Jian | ▲ Buy | Grant | 37,500 | $60K | 12/1/2025 |
| Irish Jian | ▲ Buy | Grant | 211,000 | $338K | 12/1/2025 |
| Wein Matthew | ▲ Buy | Grant | 96,000 | $154K | 12/1/2025 |
| Thomas Brian C. | ▼ Sell | Open Market | 2,701 | $5K | 9/5/2025 |
| Wapnick Pamela | ▼ Sell | Open Market | 1,576 | $3K | 9/5/2025 |
| Irish Jian | ▼ Sell | Open Market | 1,602 | $3K | 9/5/2025 |
| Wein Matthew | ▼ Sell | Open Market | 199 | $360 | 9/5/2025 |
| Wapnick Pamela | ▼ Sell | Open Market | 1,576 | $3K | 6/6/2025 |
| Thomas Brian C. | ▼ Sell | Open Market | 10,785 | $19K | 6/6/2025 |
| Irish Jian | ▼ Sell | Open Market | 6,390 | $11K | 6/6/2025 |
| Wein Matthew | ▼ Sell | Open Market | 199 | $348 | 6/6/2025 |
| Noonberg Sarah B. | ▼ Sell | Open Market | 5,239 | $9K | 6/6/2025 |
| Noonberg Sarah B. | ▲ Buy | Grant | 14,000 | $0 | 4/1/2025 |
| Wein Matthew | ▲ Buy | Grant | 3,775 | $0 | 4/1/2025 |
| Wein Matthew | ▲ Buy | Grant | 3,650 | $0 | 4/1/2025 |
| Irish Jian | ▲ Buy | Grant | 23,000 | $0 | 4/1/2025 |
| Thomas Brian C. | ▲ Buy | Grant | 32,000 | $0 | 4/1/2025 |
| Wapnick Pamela | ▲ Buy | Grant | 14,000 | $0 | 4/1/2025 |
| Wein Matthew | ▼ Sell | Open Market | 930 | $2K | 3/5/2025 |
| Wapnick Pamela | ▼ Sell | Open Market | 1,808 | $3K | 3/5/2025 |
| Wapnick Pamela | ▼ Sell | Open Market | 1,559 | $3K | 12/5/2024 |
| Wapnick Pamela | ▼ Sell | Open Market | 6,265 | $18K | 9/5/2024 |
| Irish Jian | ▲ Buy | Grant | 70,471 | $0 | 4/1/2024 |
| Borges Luis | ▲ Buy | Grant | 69,316 | $0 | 4/1/2024 |
| Wein Matthew | ▲ Buy | Grant | 10,397 | $0 | 4/1/2024 |
| Wapnick Pamela | ▲ Buy | Grant | 69,316 | $0 | 4/1/2024 |
| Noonberg Sarah B. | ▲ Buy | Grant | 57,763 | $0 | 4/1/2024 |
| Harnest Simon | ▲ Buy | Grant | 11,552 | $0 | 4/1/2024 |
| Delaney Simren | ▲ Buy | Grant | 6,931 | $0 | 4/1/2024 |
| Thomas Brian C. | ▲ Buy | Grant | 118,992 | $0 | 4/1/2024 |
| Novo Holdings A/S | ▼ Sell | Other | 839,175 | — | 2/13/2024 |
| Novo Holdings A/S | ▲ Buy | Open Market | 800,000 | $12.0M | 2/13/2024 |
| BAYER HEALTHCARE LLC | ▼ Sell | Other | 1,770,888 | — | 2/13/2024 |
| BAYER HEALTHCARE LLC | ▼ Sell | Other | 1,180,592 | — | 2/13/2024 |
| BAYER HEALTHCARE LLC | ▼ Sell | Other | 589,662 | — | 2/13/2024 |
| BAYER HEALTHCARE LLC | ▼ Sell | Other | 509,855 | — | 2/13/2024 |
| Bernales Sebastian | ▼ Sell | Other | 513,004 | — | 2/13/2024 |
| Bernales Sebastian | ▼ Sell | Other | 1,896,445 | — | 2/13/2024 |
| Novo Holdings A/S | ▲ Buy | Open Market | 100,000 | $1.0M | 2/9/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Metagenomi Therapeutics to Speak at Chardan Healthcare Conference
Metagenomi Therapeutics announced it will participate in the Chardan 10th Annual Healthcare Conference. This event provides a platform for the company to share updates with industry professionals and investors. The stock is currently trading near its 52-week low, making this upcoming presentation a notable point of interest for observers tracking the company's developments.
Metagenomi Therapeutics to Speak at Chardan Healthcare Conference. Metagenomi Therapeutics announced it will participate in the Chardan 10th Annual Healthcare Conference. This event provides a platform for the company to share updates with industry professionals and investors. The stock is currently trading near its 52-week low, making this upcoming presentation a notable point of interest for observers tracking the company's developments.